Please login to the form below

Not currently logged in
Email:
Password:

cell therapies

This page shows the latest cell therapies news and features for those working in and with pharma, biotech and healthcare.

Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

Kite was sold on to Gilead Sciences, along with FDA-approved CAR-T therapy Yescarta, one of the first two of the groundbreaking cell therapies to reach the market, just behind ... allogeneic cell therapy and the potential for greater and faster patient

Latest news

More from news
Approximately 2 fully matching, plus 93 partially matching documents found.

Latest Intelligence

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    New disruptive innovation is changing the way we create value in healthcare: big data, artificial intelligence, the growing role of patients, the discovery of new materials and biologics, gene, cell and ... This involves incorporating new diagnostic

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Between November 2016 and October 2017, the FDA approved 31 new therapies for more than 16 types of tumour, including the first cell-based therapies, the first tumour-agnostic drugs and ... cell-based therapies and oncolytic viruses that attack malignant

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    class gene or cell therapies by 2022. ... Cell and gene therapies undoubtedly do pose difficult questions – but there is also no question of holding back because of this business model uncertainty.

  • No incentive for a cure No incentive for a cure

    Cell and gene therapies in particular are heralding remarkable curative medicines, which are given only once, or over the short term. ... Healthcare systems are currently set up to cover moderate costs for chronic therapies over a medium to longer period

  • The good, the bad and the ugly The good, the bad and the ugly

    The oncology market is certainly evolving. “Some of the most interesting play is in immuno-oncology, where combination therapies are increasingly being explored. ... It will also be interesting to see how gene therapies and cell-based therapies, like

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics